A new reference material has been developed with the aim of facilitating and expediating global efforts to detect the novel coronavirus.
Developed by Texas biotech, Asuragen, the Armored RNA Quant SARS-CoV-2 Control is intended for use in developing assays in response to the Covid-19 pandemic.
Asuragen’s proprietary Armored RNA Quant technology has been included in FDA-approved assays for over 20 years and, it says, is the gold standard for reliable, traceable standards for use with molecular assays developed for virus quantitation.
The widespread and aggressive nature of Covid-19 has prompted a global effort to facilitate rapid and accurate testing for SARS-CoV-2.
The Armored RNA Quant SARS-CoV-2 Control targets the SARS-CoV-2 viral nucleocapsid (N) region and, along with the company’s new RNAse P construct, aligns with the CDC and WHO-recommended Diagnostic Panel to provide a safe, stable, and reliable way to test for the novel coronavirus.
Armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.